Reactions to HPV vaccine Gardasil rare

Although there is an effort to implement rapid response teams in hospitals throughout the country, new research suggests that they do not result in a reduced rate of cardiopulmonary arrests or deaths, according to a study in the December 3 issue of JAMA, the Journal of the American Medical Association. Previous studies have found that

Full Post: Use of rapid response team in hospital not linked with reduction in cardio arrests or deaths

Research by Australian scientists has found that adverse reactions to the HPV vaccine Gardasil are rare and most schoolgirls are able to tolerate subsequent doses.

The study led by Dr. Sharon Choo and colleagues from the Royal Children’s Hospital in Melbourne involved 25 Australian girls with suspected hypersensitivity to the vaccine.

The vaccine was given to all Australian females aged 12 to 26 years as part of a national immunisation programme beginning in 2007.

Some components of the vaccine such as aluminium salts and yeast have previously been associated with hypersensitivity reactions and some reports of adverse events followed the school vaccination programme.

The study is the first evaluation of the quadrivalent HPV vaccine after more than 380,000 vaccine doses were given in schools in Victoria and South Australia.

Thirty five schoolgirls with suspected hypersensitivity reactions including urticaria (hives), generalised rash, angioedema (swelling of subcutaneous tissues) and anaphylaxis were reported to specialised immunisation services and 25 agreed to be referred to paediatric allergy centres for further evaluation.

The researchers kept a detailed account of the reactions which included previous doses of the vaccine, time and severity of reaction, and previous clinical history and skin prick tests of the HPV vaccines were carried out.

The girls were followed-up by telephone one week after the subsequent dose and any adverse events were recorded and the research team found that only one reported a negative reaction of hives which occurred four hours after the vaccine was given.

The researchers suggest that only three of the 25 evaluated schoolgirls possibly had hypersensitivity to the vaccine, and they say true hypersensitivity is uncommon.

They say that suspected hypersensitivity reactions such as hives are often “idiosyncratic” and do not increase the risk of adverse reactions in subsequent vaccinations.

The authors recommend that girls with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and call for research into the mechanisms of hypersensitivity to the vaccine.

Gardasil and Cervarix are vaccines designed to be given to girls and young women to protect them against cancer-causing strains of the sexually transmitted human papillomavirus (HPV), which can cause cervical cancer.

Gardasil targets four strains of HPV — two responsible for cervical cancer and two causing the less serious condition of genital warts while Cervarix targets the two cancer strains.

In October this year the U.S. Centres for Disease Control and Prevention (CDC) reported that girls and young women given Gardasil were no more likely than usual to faint, have an allergic reaction, blood clot or other adverse reaction.

The research is published in the British Medical Journal.


The HPV vaccine, sold as Gardasil in the U.S., is intended to prevent four strains of the human papillomavirus, the most common sexually transmitted infection in the world. The vaccine also prevents against cervical cancer. While the vaccine represents a significant public health advance, a new article in the Journal of Law, Medicine & Ethics

Full Post: State mandates for HPV vaccination unwarranted and unwise

New industry-supported research from Finland suggests that Cervarix, an HPV vaccine given to girls in Europe and elsewhere, is safe for boys as well. “The results show that the vaccine does generate an immune response and is generally well-tolerated,” said study co-author Gary Dubin, M.D., of vaccine maker GlaxoSmithKline. It is not clear, however, whether

Full Post: Immunogenicity and safety of human papillomavirus vaccine in healthy boys

Vaccinating girls against the human papillomavirus (HPV) before they are sexually active appears to be successful in protecting them against cervical cancer, however, a Johns Hopkins University researcher and health policy expert warns it would be ill-advised to mandate vaccinations at this time. Gail Javitt, JD, MPH, is a Research Scholar at the Johns Hopkins

Full Post: Expert warns it would be ill-advised to mandate HPV vaccinations at this time

Novavax, Inc. has announced favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate. The vaccine, which does not include an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to correlate with protection against seasonal influenza disease. The Phase IIa randomized, placebo-controlled clinical trial evaluated

Full Post: Novavax announces positive results in trial of seasonal influenza VLP (trivalent) vaccine candidate

The National Association of County and City Health Officials (NACCHO) has announced a donation of up to one million doses of FluMist (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations. NACCHO will make these donated doses of vaccine available to selected state

Full Post: NACCHO to donate up to one million doses of FluMist